Community Initiated Preventive Therapy for TB (CHIP-TB)
Tuberculosis
About this trial
This is an interventional prevention trial for Tuberculosis
Eligibility Criteria
Inclusion Criteria:
Inclusion Criteria for Index Patient in South Africa:
- Adult pulmonary TB patient being treated for pulmonary TB disease (with bacteriologic confirmation including smear, GeneXpert® MTB/RIF and/or liquid mycobacterial culture) in one of the participating clinics
- Willing to have a home visit and disclose their diagnosis to household members
- Lives in the catchment areas of a study clinic
- Age 18 years or older
- Provides informed consent
Inclusion Criteria for Index Patient in Ethiopia:
- Adult or child being treated for pulmonary TB disease (clinical with or without microbiologic diagnosis) in one of the participating clinics
- Willing to have a home visit and disclose their diagnosis to household members
- Lives in the catchment areas of a study clinic
- Age 18 years or older
- Provides informed consent
Inclusion Criteria for Contact in South Africa:
- Child less than 15 years old living in the household of the TB index patient
- Caregiver willing to provide informed consent
- Children 7 years and older must also provide assent
Inclusion Criteria for Contact in Ethiopia:
- Child less than 15 years old living in the household of the TB index patient
- Caregiver willing to provide informed consent
- Children 12 years and older must also provide assent
Exclusion Criteria:
Exclusion Criteria for Index Patient in South Africa and Ethiopia:
- Extrapulmonary TB with no evidence of concurrent pulmonary TB
- Evidence of rifampin and/or isoniazid resistance on GeneXpert® MTB/RIF or drug sensitivity testing performed on M. tuberculosis isolates identified on culture
- Household has already participated in study (more than one index patient in the household) and child contacts under 15 years have already been evaluated and remain on TPT and/or TB treatment
Exclusion Criteria for Contact in South Africa:
- Household child contact of a drug-resistant TB index patient. (Drug resistance defined either by the presence of rifampin resistance on GeneXpert® MTB/RIF OR drug sensitivity testing on isolates identified by culture).
Exclusion Criteria for Contact in Ethiopia:
- Household child contact of a drug-resistant TB index patient. (Drug resistance defined either by the presence of rifampin resistance on GeneXpert® MTB/RIF OR drug sensitivity testing on isolates identified by culture).
- Household contact 15 years and older
Sites / Locations
- KNCV-Ethiopia
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Community-Based TPT Initiation
Facility-Based TPT Initiation
All TB index patients who agree to participate will have a home visit by clinic staff who will perform: (1) contact enumeration (2) TB symptom screening of all children <15 years (3) Initiation of TPT for all asymptomatic children and (4) Referral of all symptomatic children less than 15 years, including those living with HIV. HIV testing will be offered to all child contacts 12 months of age and older. Those children less than 12 months will be referred to the clinic for HIV testing, if indicated by local guidelines. In South Africa, these home visits will occur by a combination of community health workers and professional nurses. In Ethiopia, home visits will occur by health extension workers supported by nurses.
Children less than 15 years living in the home of TB index patients who agree to participate in the study will be referred to clinic for TB symptom screening and initiation of TPT for all asymptomatic child contacts. Symptomatic child contacts will be referred to a physician for evaluation, as is currently the standard of care. Additionally, child contacts identified in any maternal and child health program will be referred to the TB clinic for TB symptom screening. HIV testing will be offered at the clinic for all child contacts and will be performed according to local guideline.